News
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ ®, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness.
FDA does a 180, suspending use of Valneva's chikungunya vaccine
Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an about-face, banning the use of the shot in the United States. | Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq,
Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...
TipRanks on MSN3d
Valneva SE (ADR) trading halted, news pending
SE (ADR) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback